Media
The Australian: Racura Moves Closer To Phase 1 Trial With Key CRO Appointment
The Australian reports that Racura Oncology has appointed George Clinical as the Contract Research Organisation to support the Phase 1a/1b trial for RC220 bisantrene in solid tumour patients. Read the full article here.
Motley Fool: ASX Healthcare Stock Surges 11% On ‘Incredibly Valuable’ FDA News
The Motley Fool reports on the exciting news that Racura has received today. The US Food and Drug Administration (FDA) has extended Rare Paediatric Disease Designation to RC220 bisantrene for the treatment of paediatric acute myeloid leukemia. Read the full analysis here.
The Australian: Racura Oncology Stock Gains On US FDA Milestone
The Australian reports that The US Food and Drug Authority (FDA) has extended Rare Paediatric Disease Designation (RPDD) to Racura’s oncology drug RC220 bisantrene for paediatric acute myeloid leukemia (AML). The RPDD in paediatric AML may qualify Racura to be eligible for a Priority Review Voucher (PRV). Racura’s Executive Director, Dr Peter Smith, explains in…
Proactive: Racura Oncology At 12-Month High On Promising Preclinical Results For Drug Combination In Multiple Myeloma Treatment
Proactive reports that Racura has hit a new 12-month high on fielding some strong preclinical findings on the efficacy of lead asset bisantrene in treating multiple myeloma. Racura CEO Dr Daniel Tillett commented: “The potential for using bisantrene to not only better treat multiple myeloma, but also protect patients from the heart damage caused by carfilzomib,…
Proactive: Racura Oncology Receives FDA Orphan Drug Designation Extension For Bisantrene RC220
The United States Food and Drug Administration (FDA) has extended Orphan Drug Designation (ODD) to our proprietary formulation of bisantrene, RC220, for acute myeloid leukemia. Racura CEO Dr Daniel Tillett spoke with Proactive about this significant announcement and the commercial advantage that the ODD will bring to bisantrene. Read the full report here.
Sharewise Webinar With CEO Dr Daniel Tillett
In this webinar hosted by Sharewise, Racura Oncology CEO Dr Daniel Tillet presents the company’s current journey in the drug development process. Dr. Tillett covers bisantrene’s potential for global cancer patients, its unique ability to deliver both anti-cancer and cardioprotection, and its current stage of clinical development. He also answers a range of questions from…
Demystifying Clinical Trials & Approval Processes
In Hot Copper’s recent webinar “Demystifying clinical trials and approval processes for ASX-listed companies”, CEO Dr Daniel Tillett spoke with Sonia Madigan to discuss Racura Oncology’s journey through the drug development process. Dr Tillett shared insights into the company’s unique market position and potential growth opportunities with lead drug, bisantrene. You can watch Daniel’s interview…
The “Racura” To Beat Cancer
Racura CEO Dr Daniel Tillett sits down with Juliette Saly at ausbiz for a check-in on the company’s performance in the last quarter, and the outlook for the rest of the year. Dr Tillett says one of the most notable achievements in the quarter was the news that Racura’s RC220 bisantrene formulation met all cGMP…
Racura CEO Discusses Benefits Of Resurrecting Abandoned Drugs With Stockhead
Racura CEO Dr Daniel Tillett speaks to Nadine McGrath at Stockhead in detail about drug repurposing and resurrecting abandoned or underutilised drugs. Dr Tillet explains how commercial decisions contribute to whether a drug makes it to market or not. He further lists examples of companies that succeeded in drug repurposing. Read the full article here
